Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly)... Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs. Mehr anzeigen
Incyte (Nasdaq:INCY) announced today that it will now present at Citi’s 2024 Global Healthcare Conference on Tuesday, December 3, 2024 at 8:00 a.m. The presentation will be webcast live and can...
- 20 Präsentationen, darunter brandaktuelle, mündliche und Posterpräsentationen, beleuchten die Fortschritte bei sieben Medikamenten des Unternehmens - Die Präsentation brandaktueller Daten auf...
- Vingt présentations (dont des exposés des dernières données et des présentations sous forme d'affiches) mettront en lumière les avancées réalisées pour sept médicaments de la société - L'exposé...
- Twenty presentations, including late-breaking, oral and poster presentations, highlight advances across seven of the company’s medicines - Late-breaking data presentation at ASH will feature...
Incyte (Nasdaq:INCY) today announced that it will pause enrollment in the ongoing Phase 2 study of MRGPRX2 (INCB000262) in chronic spontaneous urticaria (CSU). The decision was made following the...
Incyte (Nasdaq: INCY) announced today that it will present at Citi’s 2024 Global Healthcare Conference on Tuesday, December 3, 2024 at 3:15 p.m. in Miami. The presentation will be webcast live...
Incyte (Nasdaq:INCY) today announced that it granted restricted stock unit awards (RSUs) representing an aggregate of 33,003 shares of the Company’s common stock and stock option awards to...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.38 | -0.506666666667 | 75 | 76.14 | 71.7207 | 1328457 | 73.53775428 | CS |
| 4 | -4.29 | -5.43657331137 | 78.91 | 83.95 | 65.02 | 2662159 | 75.70981999 | CS |
| 12 | 11.67 | 18.538522637 | 62.95 | 83.95 | 61.63 | 2051812 | 70.86307716 | CS |
| 26 | 15.95 | 27.1859553434 | 58.67 | 83.95 | 56.75 | 2627024 | 65.22362557 | CS |
| 52 | 19.34 | 34.98552822 | 55.28 | 83.95 | 50.3498 | 2340744 | 62.16967468 | CS |
| 156 | 8.59 | 13.009238225 | 66.03 | 86.29 | 50.27 | 1880819 | 67.03258268 | CS |
| 260 | -19.19 | -20.4562413389 | 93.81 | 111.05 | 50.27 | 1701701 | 72.5093646 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
